Here is What Hedge Funds Think About Affymax, Inc. (AFFY)
In the eyes of most market participants, hedge funds are perceived as slow, outdated investment vehicles of the past.
Affymax Inc (AFFY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ancora Advisors Frederick Disanto | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.09 | 14,000 | $85,260.00 | 16,540 | 2011-12-19 | Filing | |
| $6.34 | 2,540 | $16,103.60 | 2,540 | 2011-12-19 | Filing | |
| $15.25 | 652,262 | $9,946,995.50 | 2,224,407 | 2009-03-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.93 | 500 | $964.00 | 0 | 2013-08-28 | Filing | |
| $1.92 | 16,040 | $30,796.80 | 500 | 2013-08-28 | Filing | |
| $15.76 | 2,328 | $36,685.56 | 18,125 | 2013-02-15 | Filing | |
| $18.81 | 6,366 | $119,744.46 | 108,000 | 2013-02-01 | Filing | |
| $21.25 | 6,661 | $141,559.57 | 13,125 | 2013-01-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% |
News See All
Affymax, Inc. (AFFY), Coinstar, Inc. (CSTR): The NASDAQ Composite (.IXIC)'s Five Most Hated Stocks
Short-sellers certainly huffed and puffed with all of their might in May, but it wasn't meant to be: The tech-heavy NASDAQ Composite (INDEXNASDAQ:.IXIC) rose another 3.8%, extending its year-to-date gains...
Hedge Funds Are Selling Affymax, Inc. (AFFY) - Northwest Biotherapeutics, Inc (NWBO), Celsion Corporation (CLSN)
In today’s marketplace, there are many metrics investors can use to watch Mr. Market. A couple of the most under-the-radar are hedge fund and insider trading interest.
ZIOPHARM Oncology Inc. (ZIOP), Ariad Pharmaceuticals, Inc. (ARIA): 3 Reasons Investors Are Scared of Biotech Stocks
Biotechs offer the possibility of monster returns. Overnight doubles aren't out of the question.
Amgen, Inc. (AMGN), Affymax, Inc. (AFFY): The Danger of the One-Hit Wonder
The drug development field is a potentially lucrative, although always dangerous area for small companies and their investors to participate in.
3 Can't-Miss Health-Care Events This Week: Synageva BioPharma Corp (GEVA), Amedisys Inc (AMED), Gentiva Health Services, Inc. (GTIV)
You won't often hear me say this, but it's a pretty quiet week on the health-care front.
This Week in Biotech: Dynavax Technologies Corporation (DVAX), Zogenix, Inc. (ZGNX)
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
3 Stocks That May Help Determine the Dow's Moves Today: Affymax, Inc. (AFFY) and More
The Dow Jones Industrial Average finished strong last week, and eked out a closing price just above the 14,000 mark.
Behold the Dangers of a One-Trick Pony: Affymax, Inc. (AFFY) and More
At the end of last year, I proclaimed Omontys -- an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells -- as one of my 10 drugs approved by the Food and Drug Administration...
Down 85%! Why Affymax, Inc. (AFFY) is Getting Crushed This Morning
Look out below Affymax, Inc. (NASDAQ:AFFY) investors.
Billionaire Hedge Funds
